Canadian Cancer Trials Group Bulletins

General


Canadian Cancer Trials Group MA.32 in NCI Cancer Bulletin

Canadian Cancer Trials Group MA.32 -- A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer -- is highlighted in the current edition of the NCI Cancer Bulletin (http://www.cancer.gov/ncicancerbulletin/053111/page6).

Canadian Cancer Trials Group MA.32, A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer, has been accruing extremely well at about 50 patients per month within Canada. To date there are 37 sites active and 339 patients enrolled -- almost 10% of the total accrual target!

As we announced in our previous Bulletin, CTSU sites are now able to enroll their first patients. We are thankful to our U.S. colleagues for their support and welcome their participation. With approximately 200 CTSU sites eager and ready to go, we expect our accrual to increase dramatically in the coming months.

If you have any questions or would like further information about this trial, please contact Catherine Elliott, Study Coordinator for MA.32, at 613-533-6430 or celliott@ctg.queensu.ca.